Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Orthop. Nov 18, 2025; 16(11): 110420
Published online Nov 18, 2025. doi: 10.5312/wjo.v16.i11.110420
Published online Nov 18, 2025. doi: 10.5312/wjo.v16.i11.110420
Osteoporosis and fragility fractures in patients with acromegaly: A two-center cross-sectional study
Mauricio Alvarez, Oswaldo Rincon, Andres Pereira, Department of Endocrinology, Hospital Militar Central, Bogota 110221, Distrito Capital de Bogotá, Colombia
Juliana Rincon, Department of Epidemiology, Fundación Universitaria Sanitas, Bogota 110221, Colombia
Maria Mercedes Ulloa, Liliana Mejia, Alejandra Alvarado, Mónica Bernal, Department of Endocrinology, Centros Medicos Sanitas, Bogota 110221, Colombia
Author contributions: Alvarez M designed research; Alvarez M, Rincon J, Ulloa MM, Rincon O, Mejia L, Alvarado A, Pereira A, and Bernal M performed research; Alvarez M, Rincon J, Ulloa MM, Rincon O, Mejia L, Alvarado A, Pereira A, and Bernal M analyzed data; Alvarez M, Rincon J, Ulloa MM, Rincon O, Mejia L, Alvarado A, Pereira A, and Bernal M wrote the paper.
Institutional review board statement: The study was approved by the Institutional Ethics Review Board.
Informed consent statement: Patient informed consent was waived by the institutional review board due to the retrospective and anonymous nature of the data collection, posing no direct risk to the participants.
Conflict-of-interest statement: The authors declare no conflict of interest.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: Data are available upon reasonable request from the corresponding author.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mauricio Alvarez, MD, Associate Professor, Department of Endocrinology, Hospital Militar Central, Tv. 3C No. 49-02, Bogota 110221, Distrito Capital de Bogotá, Colombia. mauricioalvarez613@gmail.com
Received: June 7, 2025
Revised: July 5, 2025
Accepted: September 28, 2025
Published online: November 18, 2025
Processing time: 161 Days and 17 Hours
Revised: July 5, 2025
Accepted: September 28, 2025
Published online: November 18, 2025
Processing time: 161 Days and 17 Hours
Core Tip
Core Tip: The current study found a high prevalence of osteoporosis and non-vertebral fragility fractures in patients with acromegaly, independent of age, sex, body mass index, time from diagnosis, insulin-like growth factor level, and disease control and regardless of the presence of independent risk factors. Somatostatin analog therapy in patients with acromegaly was associated with a higher risk for having osteoporosis. Taken together, our results suggest that the severity of the disease and the need for second-line therapies, rather than a specific medication for acromegaly, may be associated with the increased risk of osteoporosis. However, further studies are required to assess the effect of somatostatin analogs on bone metabolism.